BACKGROUND: We sought to investigate the incidence of perioperative venous thromboembolism (VTE)--pulmonary embolism, superior mesenteris vein thrombosis and deep vein thrombosis--in patients with peritoneal carcinomatosis after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. METHODS: We performed cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on 60 consecutive patients with a mean age of 52 (range 24-76) years. We reviewed a prospective database recording complications and patient, tumour and surgical characteristics to determine the incidence of VTE. We reviewed hospital charts of patients with VTE to obtain clinical information including vital signs, risk factors, presence of comorbid conditions, VTE prophylaxis and subjective clinical symptoms. RESULTS: A total of 6 of 60 patients (10%) who had cytoreductive surgery and hyperthermic intraperitoneal chemotherapy experienced VTE. All patients with VTE had extensive peritoneal disease and long durations of surgery: the median duration was 431 (range 330-683) minutes. Tachycardia (mean 104 beats/min) was the only consistent abnormal vital sign recorded, with only 33% of patients experiencing clinical symptoms. CONCLUSION: This prospective study demonstrates a high rate of VTE in this patient population. Unfortunately, clinical signs and symptoms are a poor predictor of VTE. Therefore, routine screening of this specific population at high risk for VTE is warranted.
BACKGROUND: We sought to investigate the incidence of perioperative venous thromboembolism (VTE)--pulmonary embolism, superior mesenteris vein thrombosis and deep vein thrombosis--in patients with peritoneal carcinomatosis after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. METHODS: We performed cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on 60 consecutive patients with a mean age of 52 (range 24-76) years. We reviewed a prospective database recording complications and patient, tumour and surgical characteristics to determine the incidence of VTE. We reviewed hospital charts of patients with VTE to obtain clinical information including vital signs, risk factors, presence of comorbid conditions, VTE prophylaxis and subjective clinical symptoms. RESULTS: A total of 6 of 60 patients (10%) who had cytoreductive surgery and hyperthermic intraperitoneal chemotherapy experienced VTE. All patients with VTE had extensive peritoneal disease and long durations of surgery: the median duration was 431 (range 330-683) minutes. Tachycardia (mean 104 beats/min) was the only consistent abnormal vital sign recorded, with only 33% of patients experiencing clinical symptoms. CONCLUSION: This prospective study demonstrates a high rate of VTE in this patient population. Unfortunately, clinical signs and symptoms are a poor predictor of VTE. Therefore, routine screening of this specific population at high risk for VTE is warranted.
Authors: I Q Molenaar; C Legnani; T H Groenland; G Palareti; B Begliomini; O T Terpstra; R J Porte Journal: Liver Transpl Date: 2001-10 Impact factor: 5.799
Authors: Syed A Ahmad; Joseph Kim; Jeffrey J Sussman; Debbie A Soldano; Linda J Pennington; Laura E James; Andrew M Lowy Journal: Ann Surg Oncol Date: 2004-04 Impact factor: 5.344
Authors: A T Culliford; A D Brooks; S Sharma; L B Saltz; G K Schwartz; E M O'Reilly; D H Ilson; N E Kemeny; D P Kelsen; J G Guillem; W D Wong; A M Cohen; P B Paty Journal: Ann Surg Oncol Date: 2001-12 Impact factor: 5.344
Authors: Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Perry Shen; Edward A Levine; Jason Hall; Doug Case; Greg Russell; Ronald Fleming; Richard McQuellon; Kim R Geisinger; Brian W Loggie Journal: Arch Surg Date: 2003-01
Authors: Sumit Kapoor; Adel Bassily-Marcus; Rafael Alba Yunen; Parissa Tabrizian; Sabrine Semoin; Joseph Blankush; Daniel Labow; John Oropello; Anthony Manasia; Roopa Kohli-Seth Journal: World J Crit Care Med Date: 2017-05-04